DNA vaccination: Antigen presentation and the induction of immunity

Journal of Leukocyte Biology

Volumn 68, Issue 6, 2000, Pages 793-806

  Shedlock, D J ^a   Weiner, D B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cross presentation; Cross priming; DNA plasmid; DNA vaccines; Genetic adjuvant; Genetic immunization; Genetic vaccination; Immunotherapy; Prime boost

Indexed keywords

DNA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN PRESENTATION; CLINICAL TRIAL; CROSS TOLERANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG STABILITY; GENETIC TRANSFECTION; HUMAN; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INFECTION; PRIORITY JOURNAL; REVIEW; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS; DENDRITIC CELLS; DRUG ADMINISTRATION ROUTES; ENDOCYTOSIS; FORECASTING; GENE EXPRESSION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY, ACTIVE; LANGERHANS CELLS; LYMPH NODES; MUSCLE, SKELETAL; PLASMIDS; REASSORTANT VIRUSES; RECOMBINANT FUSION PROTEINS; SAFETY; TRANSFECTION; VACCINATION; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 0033664689     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. Production of neoplasms by fractions of mammalian neoplasms
2. Cloned HBV DNA causes hepatisis in chimpanzees
3. Direct transfection of viral and plasmic DNA into the liver or spleen of mice
4. Direct gene transfer into mouse muscle in vivo
5. Genetic immunization is a simple model for eliciting an immune response
6. Heterologous protection against influenza by injection of DNA encoding a viral protein
7. DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations
8. DNA inoculation induces protective in vivo immune responses against cellular challenge with HIV-1 antigen-expressing cells
9. Toward clinical trials of DNA vaccines against malaria
10. DNA vaccines for parasitic infections
11. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine
12. DNA vaccines for bacterial infections
13. Immunity to intracellular microbial pathogens
14. DNA vaccines against tuberculosis
15. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus
16. Direct gene transfer in skeletal muscle: Plasmid DNA based immunization against the hepatitis B virus surface antigen
17. Phase I safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device
18. Nucleic acid vaccine encoding gD2 protects mice from herpes simplex virus type 2 disease
19. Immunization for ebola virus infection
20. Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial
21. DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and non-human primates
22. Gene inoculation generates immune responses against human immunodeficiency virus type 1
23. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination
24. Potential DNA vaccine integration into host cell genome
25. Humoral and cellular immunity to an encoded protein induced by direct DNA injection
26. DNA vaccines
27. Potential DNA vaccine integration into host cell genome
28. Plasmid DNA malaria vaccine: The potential for genomic integration following intramuscular injection
29. The safety and longevity of DNA vaccines for fish
30. Safety and immunogenicity of HIV-1 DNA constructs in chimpanzees
31. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response
32. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans
33. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers
34. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs
35. DNA vaccines for the treatment of autoimmune disease
36. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization
37. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization
38. Bet v 1, the major birch pollen allergen, conjugated to crystalline bacterial cell surface proteins, expands allergen-specific T cells of the Th1/Th0 phenotype in vitro by induction of IL-12
39. Immune responses after immunization with plasmid DNA encoding Bet v 1, the major allergen of birch pollen
40. DNA vaccines against cancer: From genes to therapy
41. DNA-based immunization against hepatitis B surface antigen (HbsAg) in normal and HbsAg-transgenic mice
42. Genetic immunization with the free human chorionic gonadotropin β subunit elicits cytotoxic T lymphocyte responses and protects against tumor formation in mice
43. Tumor immunity and autoimmunity induced by immunization with homologous DNA
44. Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles
45. Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts
46. Intranasal administration of HIV-DNA vaccine formulated with a polymer, carboxymethylcellulose, augments mucosal antibody production and cell-mediated immune response
47. Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization
48. Class I-restricted induction by mucosal immunization with naked DNA encoding measles virus haemagglutinin
49. Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site
50. Topical gene delivery to murine skin
51. Immunization via hair follicles by topical application of naked DNA to normal skin
52. DNA immunization: Induction of higher avidity antibody and effect of route on T cell cytotoxicity
53. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine
54. DNA priming-protein boosting enhances both antigen-specific antibody and Th1-type cellular immune responses in a murine herpes simplex virus-2 gD vaccine model
55. Novel strategies using DNA for the induction of mucosal immunity
56. Mucosal immunization with DNA vaccines
57. Dendritic cells in genetic immunization
58. Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations
59. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses
60. Cloning of a second dendritic cell-associated C-type lectin (dectin-2) and its alternatively spliced isoforms
61. Dendritic cells and the control of immunity
62. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
63. Help for cytotoxic-T-cell responses is mediated by CD40 signaling
64. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
65. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization
66. Gene vaccination with naked piasmid DNA: Mechanism of CTL priming
67. The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites
68. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization
69. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma
70. Biological features of genetic immunization
71. Activation of cutaneous dendritic cells by CpG-containing oligodeoxy-nucleotides: A role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA
72. DNA vaccination: Transfection and activation of dendritic cells as key events for immunity
73. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope
74. DNA-based immunization by in vivo transfection of dendritic cells
75. Specific immune induction following through in vivo transfection and activation of macrophages/antigen-presenting cells
76. Quantitative analysis of the immunopotency of genetically transfected dendritic cells
77. 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
78. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
79. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay
80. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help
81. Expression of a viral protein by muscle cells in vivo induces protective cell-mediated immunity
82. Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: Antigen presentation by nonmuscle cells
83. Role of bone marrow-derived cells in presenting MHC class I-mediated tumor antigens
84. Bystander apoptosis triggers dendritic cell maturation and antigen presenting function
85. Dendritic cell presentation of antigens from apoptotic cells in a proinflammatory context
86. + T cells
87. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction
88. + T cells induced by cross-presentation of self-antigens involves signaling through CD95 (fas, apo-1)
89. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRIAL)
90. Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques
91. Role of cytokines in determining T-lymphocyte function
92. Systemic immunological effects of cytokine genes injected into skeletal muscle
93. Coadministration of IL-12 or IL-10 expression cassettes drives immune responses toward a Th1 phenotype
94. + T cell-mediated protective immunity against herpes simplex virus-2 challenge
95. In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model
96. Antigen-specific humoral and cellular immune responses can be modulated in rhesus macaques through the use of IFN-γ, IL-12, or IL-18 gene adjuvants
97. HIV-1 DNA vaccines and chemokines
98. Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV
99. Modulation of amplitude and direction of in vivo immune responses by coadministration of cytokine gene expression cassettes with DNA immunogens
100. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases
101. In vivo cytokine gene transfer by gene gun reduces tumor growth in mice
102. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys
103. Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants
104. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines
105. Macrophage colony-stimulating factor can modulate immune responses and attract dendritic cells in vivo
106. Protective immunity against heterologous challenge with encephalomyocarditis virus by VP1 DNA vaccination: Effect of co-injection with a GM-CSF gene
107. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccine augmented with cytokine-expressing plasmids
108. Development of a multicomponent candidate vaccine for HIV-1
109. CD86 (B7-2) can function to drive MHC-restricted antigen-specific CTL responses in vivo
110. Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis
111. The degradation signal in a short-lived protein
112. Chemical denaturation and modification of ovalbumin alters its dependence on ubiquitin conjugation for class I antigen presentation
113. DNA immunization: Ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction
114. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen
115. Increasing gene expression in yeast by fusion to ubiquitin
116. Induction of enhanced CTL-dependent protective immunity in vivo by N-end rule targeting of a model tumor antigen
117. Induction of MHC class I-restricted CTL response by DNA immunization with ubiquitin-influenza virus nucleoprotein fusion antigens
118. + T cell responses
119. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction
120. Improvement of the immune response against plasmid DNA encoding OspC of borrelia by an ER-targeting leader sequence
121. Protective immune correlates can segregate by vaccine type in a murine herpes model system
122. Toward an HIV-type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies
123. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination
124. Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts
125. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine
126. + T cell immunogenicity and protective efficacy in the influenza and malaria models
127. + T cells using heterologous prime-boost immunisation strategies
128. Improving protective immunity induced by DNA-based immunization: Priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus
129. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus
130. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
131. + T cells
132. + T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression